HONG KONG, Sept. 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225). The trial will evaluate cadonilimab, Akeso's...
Hence then, the article about akeso announces first patient dose in global registrational trial of cadonilimab pd 1 ctla 4 for pd 1 treatment resistant hepatocellular carcinoma was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Announces First Patient Dose in Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma )
Also on site :
- ‘The Young and the Restless’ Star Dee Freeman Dead at 66
- “Esto es una recalibración”: el gabinete de Trump teme que nadie esté a salvo tras los despidos de Bondi y Noem
- New Uncharted game teased? Director post hints at franchise return